Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Antimicrobial Resistance with Bacterial Causes of Community-Acquired Respiratory Tract Infections in the United States

  • 7 Accesses

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Spika JS, Facklam RR, Plikaytis BD, Oxtoby MJ. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979–1987. J Infect Dis 1991 Jun; 163(6): 1273–8

  2. 2.

    Jorgensen JH, Doern GV, Maher LA, et al. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 1990 Nov; 34(11): 2075–80

  3. 3.

    Doern GV, Richter SS, Miller A, et al. Antimicrobial resistance with Streptococcus pneumoniae in the United States–as fluoroquinolones resistance emerges, have we turned the corner on resistance to other antimicrobial classes? Clin Infect Dis. In press

  4. 4.

    Karlowsky JA, Thornsberry C, Jones ME, et al. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998–2002). Clin Infect Dis 2003 May 15; 36(8): 963–70

  5. 5.

    Brown SD, Farrell DJ. Antibacterial susceptibility among Streptococcus pneumoniae isolated from paediatric and adult patients as part of the PROTEKT US study in 2001–2002. J Antimicrob Chemother 2004 Sep; 54 Suppl 1: i23–i29

  6. 6.

    Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997–2002). Diagn Microbiol Infect Dis 2004 Oct; 50(1): 59–69

  7. 7.

    Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003 Aug; 52(2): 229–46

  8. 8.

    McCormick AW, Whitney CG, Farley MM, et al. Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med 2003 May; 9(4): 424–30

  9. 9.

    Schrag S J, McGee L, Whitney CG, et al. Emergence of Streptococcus pneumoniae with very-high-level resistance to penicillin. Antimicrob Agents Chemother 2004 Sep; 48(8): 3016–23

  10. 10.

    Brueggemann AB, Pfaller MA, Doern GV. Use of penicillin MICs to predict in vitro activity of other beta-lactam antimicrobial agents against Streptococcus pneumoniae. J Clin Microbiol 2001 Feb; 39(1): 367–9

  11. 11.

    Shortridge VD, Doern GV, Brueggemann AB, et al. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994–1995. Clin Infect Dis 1999 Nov; 29(5): 1186–8

  12. 12.

    Zhanel GG, Palatnick L, Nichol KA, et al. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003 Jun; 47(6): 1867–74

  13. 13.

    Low DE, de Azavedo J, Weiss K, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob Agents Chemother 2002 May; 46(5): 1295–301

  14. 14.

    Aspa J, Rajas O, Rodriguez de Castro F, et al. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin Infect Dis 2004 Mar 15; 38(6): 787–98

  15. 15.

    Reinert RR, Al Lahham A, Lemperle M, et al. Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. J Antimicrob Chemother 2002 Feb; 49(1): 61–8

  16. 16.

    Hoban DJ, Doern GV, Fluit AC, et al. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin Infect Dis 2001 Jun 15; 32 Suppl 2: S81–S93

  17. 17.

    Farrell DJ, Morrissey I, Bakker S, Felmingham D. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999–2000 study. J Antimicrob Chemother 2002 Sep; 50 Suppl S1: 39–47

  18. 18.

    Farrell DJ, Douthwaite S, Morrissey I, et al. Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999–2000 study. Antimicrob Agents Chemother 2003 Jun; 47(6): 1777–83

  19. 19.

    Doern GV, Brueggemann A, Holley Jr HP, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996 May; 40(5): 1208–13

  20. 20.

    Doern GV, Brueggemann AB, Huynh H, Wingert E. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997–98. Emerg Infect Dis 1999 Nov; 5(6): 757–65

  21. 21.

    Doern GV, Heilmann KP, Huynh HK, et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999–2000, including a comparison of resistance rates since 1994–1995. Antimicrob Agents Chemother 2001 Jun; 45(6): 1721–9

  22. 22.

    Brueggemann AB, Coffman SL, Rhomberg P, et al. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994–1995. Antimicrob Agents Chemother 2002 Mar; 46(3): 680–8

  23. 23.

    Richter SS, Heilmann KP, Beekmann SE, et al. Molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations. Clin Infect Dis. In press

  24. 24.

    MacGowan AP, Bowker KE. Mechanism of fluoroquinolone resistance is an important factor in determining the antimicrobial effect of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 2003 Mar; 47(3): 1096–100

  25. 25.

    Farrell DJ, Morrissey I, Bakker S, et al. In vitro activities of telithromycin, line-zolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations. Antimicrob Agents Chemother 2004 Aug; 48(8): 3169–71

  26. 26.

    Richter SS, Heilmann KP, Coffman SL, et al. The molecular epidemiology of penicillin-resistant Streptococcus pneumoniae in the United States, 1994–2000. Clin Infect Dis 2002 Mar 1; 34(3): 330–9

  27. 27.

    Richter SS, Brueggemann AB, Huynh HK, et al. A 1997-1998 national surveillance study: Moraxella catarrhalis and Haemophilus influenzae antimicrobial resistance in 34 US institutions. Int J Antimicrob Agents 1999 Nov; 13(2): 99–107

  28. 28.

    Thornsberry C, Ogilvie P, Kahn J, Mauriz Y. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996–1997 respiratory season. Diagn Microbiol Infect Dis 1997; 29(4): 249–57

  29. 29.

    Doern GV, Brueggemann AB, Pierce G, et al. Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996; 40(12): 2884–6

Download references

Author information

Correspondence to Dr Gary V. Doern.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Doern, G.V. Antimicrobial Resistance with Bacterial Causes of Community-Acquired Respiratory Tract Infections in the United States. Treat Respir Med 4, 1–4 (2005). https://doi.org/10.2165/00151829-200504001-00003

Download citation

Keywords

  • Antimicrobial Resistance
  • Streptococcus Pneumoniae
  • Haemophilus Influenzae
  • Antimicrob Agent
  • Cefpodoxime